Jie Bao

Jie Bao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
YHYing Hou
Ying Hou
YZYi-Hong Zhang
Yi-Hong Zhang
JBJie Bao
Jie Bao
MBMei-Ling Bao
Mei-Ling Bao
GYGuang Yang
Guang Yang
YZYu-Dong Zhang
Yu-Dong Zhang

1 June 2021 in EBioMedicine
Verified
Journal Article
Open access
YHYing Hou
Ying Hou
JBJie Bao
Jie Bao
YSYang Song
Yang Song
MBMei-Ling Bao
Mei-Ling Bao
KJKe-Wen Jiang
Ke-Wen Jiang
YZYu-Dong Zhang
Yu-Dong Zhang
Accurate identification of pelvic lymph node metastasis (PLNM) in patients with prostate cancer (PCa) is crucial for determining appropriate treatment options. Here, we built a PLNM-Risk calculator to obtain a precisely informed decision about whether to perform extended pelvic lymph node dissection (ePLND). The PLNM-Risk calculator was developed in 280 patients and verified internally in 71 patients and externally in 50 patients by integrating a set of radiologists' interpretations, clinicopathological factors and newly refined imaging indicators from MR images with radiomics machine learning and deep transfer learning algorithms. Its clinical applicability was compared with Briganti and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms. The PLNM-Risk achieved good diagnostic discrimination with areas under the receiver operating characteristic curve (AUCs) of 0.93 (95% CI, 0.90-0.96), 0.92 (95% CI, 0.84-0.97) and 0.76 (95% CI, 0.62-0.87) in the training/validation, internal test and external test cohorts, respectively. If the number of ePLNDs missed was controlled at < 2%, PLNM-Risk provided both a higher number of ePLNDs spared (PLNM-Risk 59.6% vs MSKCC 44.9% vs Briganti 38.9%) and a lower number of false positives (PLNM-Risk 59.3% vs MSKCC 70.1% and Briganti 72.7%). In follow-up, patients stratified by the PLNM-Risk calculator showed significantly different biochemical recurrence rates after surgery. The PLNM-Risk calculator offers a noninvasive clinical biomarker to predict PLNM for patients with PCa. It shows improved accuracy of diagnosis support and reduced overtreatment burdens for patients with findings suggestive of PCa. This work was supported by the Key Research and Development Program of Jiangsu Province (BE2017756) and the Suzhou Science and Technology Bureau-Science and Technology Demonstration Project (SS201808).

24 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
PJPengfei Jin
Pengfei Jin
LYLiqin Yang
Liqin Yang
XQXiaomeng Qiao
Xiaomeng Qiao
CHChunhong Hu
Chunhong Hu
CHChenhan Hu
Chenhan Hu
JBJie Bao
Jie Bao
Purpose: To determine the predictive performance of the integrated model based on clinical factors and radiomic features for the accurate identification of clinically significant prostate cancer (csPCa) among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions.Materials and Methods: A retrospective study of 103 patients with PI-RADS 3 lesions who underwent pre-operative 3.0-T MRI was performed. Patients were randomly divided into the training set and the testing set at a ratio of 7:3. Radiomic features were extracted from axial T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images of each patient. The minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) feature selection methods were used to identify the radiomic features and construct a radiomic model for csPCa identification. Moreover, multivariable logistic regression analysis was used to integrate the clinical factors with radiomic feature model to further improve the accuracy of csPCa identification, and the two are presented in the form of normogram. The performance of the integrated model was compared with radiomic model and clinical model on testing set.Results: A total of four radiomic features were selected and used for radiomic model construction producing a radiomic score (Radscore). Radscore was significantly different between the csPCa and the non-csPCa patients (training set: p < 0.001; testing set: p = 0.035). Multivariable logistic regression analysis showed that age and PSA could be used as independent predictors for csPCa identification. The clinical–radiomic model produced the receiver operating characteristic (ROC) curve (AUC) in the testing set was 0.88 (95%CI, 0.75–1.00), which was similar to clinical model (AUC = 0.85; 95%CI, 0.52–0.90) (p = 0.048) and higher than the radiomic model (AUC = 0.71; 95%CI, 0.68–1.00) (p < 0.001). The decision curve analysis implies that the clinical–radiomic model could be beneficial in identifying csPCa among PI-RADS 3 lesions.Conclusion: The clinical–radiomic model could effectively identify csPCa among biparametric PI-RADS 3 lesions and thus could help avoid unnecessary biopsy and improve the life quality of patients.

1 July 2023 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
LYLiqin Yang
Liqin Yang
PJPengfei Jin
Pengfei Jin
JQJing Qian
Jing Qian
XQXiaomeng Qiao
Xiaomeng Qiao
JBJie Bao
Jie Bao
XWXIMING Wang
XIMING Wang
Background: Extracapsular extension (ECE) of prostate cancer (PCa) is closely related to the treatment and prognosis of patients, and radiomics has been widely used in the study of PCa. This study aimed to evaluate the value of a combined model considering magnetic resonance imaging (MRI)-based radiomics and clinical parameters for predicting ECE in PCa. Methods: A total of 392 PCa patients enrolled in this retrospective study were randomly divided into the training and validation sets at a ratio of 7:3. Radiologists assessed all lesions by Mehralivand grade. Radiomics features were extracted and selected to build a radiomics model, while clinical parameters were noted to construct the clinical model. The combined model was constructed by the integration of the radiomics model and clinical model. Meanwhile, the nomogram for predicting ECE was constructed based on the combined model. Then, the area under the receiver operating characteristic (ROC) curve (AUC), Delong test and the decision curve analysis (DCA) were used to compare the performance among the combined model, radiomics model, clinical model and Mehralivand grade. Results: The AUC of the combined model in the validation set was comparable to that of the radiomics model [AUC =0.894 (95% confidence interval (CI): 0.837–0.950) vs. 0.835 (95% CI: 0.763–0.908), P>0.05]. In addition, the sensitivity of the combined model and radiomics model was 90.7% and 77.8%, with an accuracy of 81.4% and 76.3%, respectively. On the other hand, the AUCs of the Mehralivand grade of radiologists and clinical model were 0.774 (95% CI: 0.691–0.857) and 0.749 (95% CI: 0.658–0.840), respectively, in the validation set, which were lower than those in the combined model (P<0.05). The DCA implied that the combined model could obtain the maximum net clinical benefits compared with the clinical model, the Mehralivand grade and radiomics model. Conclusions: The combined model has a satisfactory predictive value for ECE in PCa patients compared with the clinical model, Mehralivand grade of radiologists, and the radiomics model.

25 July 2026 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
XFXu Fu
Xu Fu
JBJie Bao
Jie Bao
XQXiaomeng Qiao
Xiaomeng Qiao
JSJunkang Shen
Junkang Shen
YZYueyue Zhang
Yueyue Zhang
JLJiangang Liu
Jiangang Liu